SIRT2 and non-small cell lung carcinoma: Increased acetylation of Sirt1 substrate p53 and Sirt2 substrate α-tubulin demonstrated that selective Sirt1 and Sirt2 inhibitors possessed on-target cellular activity in the NCI-H460 NSCLC cell line [137].